Research has shed important new light on the enemies-turned-allies that allow bacteria to exchange genes, including those ...
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...
Researchers from North Carolina State University have successfully synthesized bacteriochlorophyll a, which is a ...
Longhorn Vaccines and Diagnostics (LHNVD), an IND enabling-stage biopharmaceutical company, today announced it will present ...
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream ...
Recce is developing a new class of antibiotics to tackle drug-resistant superbugs almost a century after the development of ...
HYDERABAD: A collaborative study by scientists from CSIR-Centre for Cellular and Molecular Biology and LV Prasad Eye ...
Hyderabad: A joint study by the Centre for Cellular and Molecular Biology (CCMB) and L V Prasad Eye Institute (LVPEI) has ...
Researchers from the CSIR-Centre for Cellular and Molecular Biology (CCMB) and the LV Prasad Eye Institute have found alarming levels of antimicrobial resistance (AMR) in bacteria causing eye ...
A collaborative study by CCMB and LVPEI reveals alarming antimicrobial resistance in eye infection bacteria in India. Over 45% of isolates are multidrug-resistant, including vancomycin-resistant ...
The new guidance was issued on Monday and concerns bacteria that can cause serious health complications for some people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results